摘要
HIV-1病毒为包膜病毒,其感染靶细胞的第一步是由HIV包膜蛋白表面亚基gp120与靶细胞上的CD4分子和辅助受体(趋化因子受体CCR5或CXCR4等)结合,导致gp41的构型发生改变,启动病毒包膜与靶细胞膜的融合。与gp120相结合的一些抗体、蛋白、多糖、多肽和小分子化合物,都可能影响HIV-1病毒包膜和靶细胞膜融合的过程,从而起到抗HIV-1病毒的作用。该文对近年来以HIV gp120为靶点的HIV进入抑制剂的研究进展进行综述。
HIV-1 is an envelope virus.Two glycoprotein subunits,gp120 and gp41,are on the virus membrane and mediate the virus entry.The membrane fusion events leading to HIV entry into the target cell are initiated by the binding of gp120 to CD4 and subsequently to a co-receptor,CXCR4 or CCR5.Then the conformation of gp41 has also changed,resulting in the fusion between the viral and cellular membranes.Many antibodies,proteins,saccharides,peptides and small molecule compounds which bind to gp120 can deter the progress of virus entry.This review discusses recent progress in the development of anti-HIV agents targeting gp120.
出处
《国际药学研究杂志》
CAS
2011年第2期89-95,共7页
Journal of International Pharmaceutical Research
基金
国家自然科学基金-广东省联合基金重点项目(U0832001)
霍英东高等院校青年教师基金(111045)
